F-Star Therapeutics
United Kingdom
acquiredseries-a
series-a
Stage
1
Investors
About
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on developing tetravalent bispecific antibodies for cancer and serious illnesses, with a pipeline including FS118, FS120, FS222, and SB 11285 targeting various immune evasion pathways.
Explore F-Star Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.